Investors can effectively unlock financial freedom with dividend stocks to buy for a passive income stream. The key to invest in dividend stocks, promising a consistent and growing payout while offering steady capital gains. These assets stand as beacons of stability amidst the turbulence in the stock market, offering a slow but sure path to wealth accumulation.Companies that have maintained a healthy track record of dividend payments exemplify resilience, capable of weathering virtually any economic fluctu ...

公司战略 - AbbVie计划在本十年实现高个位数的复合年增长率[6] - 公司计划在2025年前开始明确未来的长期发展计划[12] - Cerevel公司对于Serial交易和emraclidine的前景感到兴奋，认为这将有助于推动神经科学领域的长期增长[32] 产品研发 - Telisotuzumab针对EGFR野生型患者的观察显示35%的ORR，9个月的DOR，以及14个月以上的中位总生存期[21] - 400作为下一代c-Met抗体在结直肠癌中表现出很强的疗效，将在肺癌和胃食道癌中展示数据[24] - Emraclidine在1B阶段表现出很高的疗效，期待Phase 2数据展示类似的结果[27] 产品市场表现 - SKYRIZI在2024年的增长预期为27亿美元，其中银屑病领域增长17亿美元，肠炎领域增长10亿美元[34] - 银屑病领域的市场份额约为50%，处方份额在中30%左右[34] - RINVOQ在各个适应症中都成为了领先的二线加产品，尽管在一些适应症中失去了一线使用的地位，但在二线和三线市场上表现强劲，去年增长了近60%[50] 未来展望 - Telisotuzumab有望在FDA获得加速批准，同时正在进行针对化疗的第三期临床试验[22] - 公司目前尚未明确表达关于未来业务规模的预期[18] - 公司对保持平价准入感到满意，预计在2025年前会开始出现尾部效应[13]

公司管理团队 - AbbVie Inc.在第44届年度医疗保健大会上展示了公司管理团队[1] - 新任CEO表示将确保过渡尽可能顺利[3] 未来发展规划 - 公司计划在未来十年实现高个位数增长[4] - 公司对2024年的业务进展感到满意[9] 产品表现 - Humira产品在2023年表现出色，公司对未来保持乐观[5] - Telisotuzumab的数据显示潜在的加速批准机会[21] - Emraclidine在精神分裂症治疗方面表现出色，具有较高的疗效和安全性[26][28] - SKYRIZI在银屑病领域表现强劲，预计增长约27亿美元，市场份额约50%[32] - SKYRIZI在克罗恩病领域也表现出色，预计销售额将翻倍[33] - SKYRIZI在溃疡性结肠炎领域表现强劲，维持了安慰剂患者的病情[35] - RINVOQ在二线治疗中表现出色，成为领先产品[48] - VRAYLAR在自闭症谱系障碍领域的数据即将发布，公司希望大家关注其在双相情感障碍和其他领域的表现[53] 市场前景 - 公司非常兴奋关于连续交易，扩展了在精神病学领域的存在[30] - 公司在美国市场成功调整策略，继续增长业务[49] - 公司正在研发短效Bonti，以满足那些担心长效BOTOX的患者需求[50] - AbbVie的增长平台是一个重要的驱动因素[54] - 投资者对AbbVie的未来更加乐观，预期高个位数增长[54] - 公司的产品管道有望带来惊喜，特别是BCMA CD3双特异性383和400[55]

PALM BEACH, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other parts of the world is one of the factors driving the need for the drugs used in the treatment. Moreover, the prevalence is significantly higher in the geriatric population compared to other types of cancers. Thus, an increase in the geriatric population is one factor driving the pancrea ...

THE FIRST AND ONLY HYALURONIC ACID DERMAL FILLER APPROVED FOR THE IMPROVEMENT OF MODERATE TO SEVERE TEMPLE HOLLOWING1 IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.1 JUVÉDERM® VOLUMA® XC is the first and only hyaluronic acid (HA) dermal filler to receive U.S. FDA approval for the impr ...

Dragonfly Therapeutics - Dragonfly Therapeutics是一家临床阶段的生物技术公司，致力于发现、开发和商业化利用人体免疫系统的新疗法，为患者带来突破性治疗方案[5] - Dragonfly的平台技术已经有第八种药物进入临床试验，其中第六种TriNKET®正在进行临床试验[1] AbbVie - AbbVie（NYSE: ABBV）对ABBV-303进行了临床试验，这是第一种由AbbVie授权的TriNKET®药物候选进入临床试验[3] - AbbVie已经将ABBV-303推进到临床试验阶段，这是对患有复杂疾病的患者提供潜在新治疗选择的重要进展[4]

Investing in dividend kings is about keeping things simple. A distinguishing feature of these companies is a rock-solid balance sheet that allows them to demonstrate unwavering commitment to building shareholder value. In fact, to become a dividend king a company must increase their dividend for at least 50 consecutive years.  You won’t find these companies on any “Magnificent 7” list of tech stocks. They aren’t going to be leading the AI revolution or renewable energy transformation. However, what dividend ...

公司表现 - AbbVie (ABBV) 最新收盘价为178.91美元，较上一交易日上涨1.62%[1] - 过去一个月，该药企股价上涨了5.05%，超过了医疗行业的3.58%增幅[2] - AbbVie目前的Forward P/E比率为15.79，高于行业平均值14.9，显示公司的股价溢价[7] 分析师预测 - 分析师预计AbbVie即将发布的每股收益为2.34美元，较去年同期下降了4.88%；预计营收为119.4亿美元，较去年同期下降了2.31%[3] - Zacks Consensus Estimates预测AbbVie全年每股收益为11.15美元，营收为545亿美元，较去年分别增长了0.36%和0.33%[4] - 投资者应关注分析师对AbbVie的最新预测变化，积极的变化代表分析师对公司业务和盈利能力的乐观态度[5] 行业比较 - ABBV的PEG比率为2.24，高于昨日收盘价的Large Cap Pharmaceuticals行业平均值1.67[8] - Large Cap Pharmaceuticals行业属于医疗行业，行业排名为177，属于所有250+行业中的后30%[9] - Zacks Industry Rank通过测量组内个股的平均Zacks Rank来评估行业群体的实力，研究显示排名前50%的行业胜过后50%的行业[10] 建议 - 研究表明，预测变化与未来股价表现直接相关，公司开发了Zacks Rank模型，考虑这些预测变化并提供可操作的评级系统[6] - 使用Zacks.com监控所有这些影响股价的指标，并在未来交易中持续关注[11]

It’s often said that patience is a virtue for investors that often means taking advantage of the stability of blue-chip stocks.  However, that virtue can be sorely lacking among investors. In good times, investors are frequently drawn to the next shiny object. And when growth is hard to come by, they can move into more speculative assets, seeking growth at all costs. But history says investors with a long-term focus can still do better looking at solid blue-chip stocks. These stocks frequently are in defens ...

Since the beginning of the 20th century, dividend stocks have accounted for 75% of the total returns in the U.S. stock market. Dividend growth stocks, which are companies that regularly increase their cash payouts to shareholders annually, have significantly outperformed the majority of other asset classes over this 124-year span.The primary reason for this is the power of compounding. By owning a dividend growth stock and reinvesting the dividends each quarter, your investment can experience exponential gr ...